- freely available
Int. J. Mol. Sci. 2013, 14(6), 11742-11766; doi:10.3390/ijms140611742
Published: 31 May 2013
Abstract: Melatonin is the major secretory product of the pineal gland during the night and has multiple activities including the regulation of circadian and seasonal rhythms, and antioxidant and anti-inflammatory effects. It also possesses the ability to modulate immune responses by regulation of the T helper 1/2 balance and cytokine production. Autoimmune diseases, which result from the activation of immune cells by autoantigens released from normal tissues, affect around 5% of the population. Activation of autoantigen-specific immune cells leads to subsequent damage of target tissues by these activated cells. Melatonin therapy has been investigated in several animal models of autoimmune disease, where it has a beneficial effect in a number of models excepting rheumatoid arthritis, and has been evaluated in clinical autoimmune diseases including rheumatoid arthritis and ulcerative colitis. This review summarizes and highlights the role and the modulatory effects of melatonin in several inflammatory autoimmune diseases including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, and inflammatory bowel disease.
1. Introduction of Melatonin
1.1. The Discovery, Biosynthesis and Biological Function of Melatonin
In 1917, McCord and Allen found that a substance extracted from bovine pineal gland could whiten the skin of Rana pipiens and named this substance melatonin (N-acetyl-5-methoxytryptamine). Melatonin is a product of the amino acid tryptophan. Tryptophan taken up by cells is first hydroxylated by tryptophan hydroxylase and then decarboxylated by decarboxylase, resulting in the formation of 5-hydroxytryptamine (serotonin). Serotonin is then N-acetylated by N-acetyltransferase (NAT) to form N-acetylserotonin. The final enzyme in the process of melatonin synthesis is hydroxyindole-O-methyltransferase (HIOMT), which O-methylates N-acetylserotonin and forms melatonin.
Melatonin is the major secretory hormone produced by the pineal gland during the night and has multifunctional properties . It regulates circadian and seasonal rhythms [2,3], and is an effective antioxidant and scavenger of free radicals [4–6]. In the liver, melatonin is degraded enzymatically to 6-hydroxymelatonin . As part of the process of scavenging free radicals and reactive species, this indoleamine generates other metabolites including cyclic 3-hydroxymelatonin, which is generated when melatonin scavenges two highly toxic hydroxyl radicals . Melatonin is also secreted by neuroendocrine cells in the gastrointestinal tract (GIT), and its antioxidant action plays a role in protection of gastrointestinal mucosa from ulceration . The effect of melatonin in the GIT has been suggested to include protection of the pancreas from acute pancreatitis . Furthermore, an earlier study found that NAT and HIOMT, two key enzymes in the synthesis process of melatonin, are expressed in various extrapineal tissues of Sprague-Dawley (SD) rats, including kidney, muscle, testis and the organs of central nervous systems. NAT mRNA is also presented in the spleen while HIOMT is undetectable in this organ . Gomez-Corvera et al. also demonstrated that mRNA of NAT is expressed in thymus, spleen, bone marrow and peripheral blood mononuclear cells (PBMCs) of mice, and the presence of melatonin is detectable in these tissues . Carrillo-Vico et al. found that human PBMCs express NAT and HIOMT, and these enzymes are capable of synthesis of melatonin . Moreover, there are studies that have reported the synthesis of melatonin in the thymus and bone marrow of humans [14,15]. The presence of, either enzymes involved in the synthesis of melatonin, or melatonin itself, in the immune tissues suggests a role of melatonin in the immune system.
1.2. The Effect of Melatonin on the Immune System
Recent studies have confirmed that melatonin plays an important role in the immune system . Melatonin receptors are expressed on the membrane of CD4 T cells, CD8 T cells, and B cells [17,18]. It has been reported that the proliferation of T cells increases in mice treated with melatonin . Melatonin treatment has also been reported to enhance the production of natural killer (NK) cells and monocytes in the bone marrow of mice , and can induce cytokine production in human peripheral blood mononuclear cells via the nuclear melatonin receptor . By contrast, other studies have demonstrated that the expression of interleukin (IL)-2 and interferon (IFN)-γ is decreased and the expression of T helper (Th)2 cell cytokines, such as IL-4 and IL-10, is upregulated in mice treated with melatonin [22–24].
An antiproliferative effect of melatonin on lymphocyte-derived tumor cells has also been described. Raghavendra et al. demonstrated that melatonin inhibits the proliferation of 3DO.54.8-Th1-hybridoma cells by downregulating IL-2 secretion in these cells . Majewska et al. suggested that melatonin suppresses cell-mediated immune responses partly through inhibiting the production of IL-12 in antigen-presenting cells (APC) . Konakchieva et al. also reported that melatonin inhibits Concanavalin A-induced [3H]-thymidine incorporation in human peripheral blood lymphocytes and tonsillar lymphocytes . Thus, melatonin can have dichotomous effects in the immune system by either activating or suppressing immune cells.
1.3. The Effect of Melatonin on the Production of Proinflammatory Cytokines
The effect of melatonin on the suppression of proinflammatory cytokine production has been proved in several earlier studies. Raghavendra et al. demonstrated that melatonin suppresses the production of tumor necrosis factor (TNF)-α. Wang et al. also demonstrated that melatonin decreases the production of proinflammatory cytokines including TNF-α and IL-1β from Kupffer cells in fibrotic rats. Melatonin also protects against experimental reflux esophagitis by repressing the upregulation of TNF-α, IL-1β, and IL-6 . Nitric oxide has been found to be an important mediator in inflammatory response . Melatonin also plays a role in the regulation of nitric oxide synthesis . Previous study has shown that melatonin inhibits the expression of inducible nitric oxide synthase (iNOS) in liver and lung of lipopolysaccharide (LPS)-treated rat . The in vivo study presented by Jung et al. also observed that melatonin intraperitoneal (i.p.) administration (50 mg/kg) in rats suppresses the mRNA expression of TNF-α, IL-1β, IL-6 and iNOS . Veneroso et al. also found that melatonin administration at a lower dose (1 mg/kg, i.p.) decreases the mRNA levels of proinflammatory cytokines and protein level of iNOS and cyclooxygenase-2 (COX-2) in rats induced with cardiac inflammatory injury by acute exercise . Furthermore, the protective role of melatonin in mitochondria dysfunction has been documented. Melatonin treatment prevents mitochondrial impairment and inhibits inducible mitochondrial NOS activity in septic mice [34,35]. The study presented by Lowes et al. also supports that melatonin reduces the production of IL-6 and IL-8, and prevents the loss of mitochondrial membrane potential in endothelial cells treated with LPS plus peptidoglycan G (PepG) . Recently, they further proved that in vivo melatonin i.v. administration results in the reduction of serum IL-6 and the improvement of mitochondrial function in LPS plus PepG-induced acute sepsis in rats . The mechanism of melatonin in the reduction of proinflammatory cytokine as well as iNOS production has been suggested via the inhibition of either expression or activation of nuclear factor-κB (NF-κB).
1.4. The Suppressive Effect of Melatonin on the Activation of NF-κB
NF-κB activation initiates the expression of genes involved in the inflammatory responses, such as proinflammatory cytokines, iNOS, adhesion molecules, COX-2, and matrix metalloproteinases (MMPs) . Earlier studies have demonstrated that melatonin reduces the transcriptional activity and DNA binding of NF-κB by preventing its translocation to the nucleus . This results in the reduction of proinflammatory cytokine and chemokine production. The expression of adhesion molecules regulated by NF-κB is also suppressed by melatonin , resulting in reduced recruitment of neutrophils to inflamed sites [41,42]. Gilad et al. demonstrated that melatonin suppresses the expression of iNOS in murine macrophages via suppression of NF-κB .
Recently, many studies confirmed that melatonin exerts anti-inflammatory effect through inhibition of NF-κB. Some of these studies found that the expression level of NF-κB was suppressed by melatonin treatment [44–47], while others suggested that melatonin mainly disturbed the translocation of NF-κB. In the in vitro studies, Qin et al. demonstrated that melatonin (10 μM) inhibits IL-1μ-induced expression and activation of MMP 9 in human umbilical vein endothelial cells (HUVECs) by suppressing NF-κB expression . By contrast, Xia et al. revealed that melatonin treatment at 1 mM concentration attenuates LPS-induced upregulation of cyclooxygenase-2 (COX-2) and iNOS expression and inhibits the translocation of NF-κB in RAW264.7 cells via modulation of toll-like receptor 4-mediated signaling pathways . The research in human chondrocyte cell line (CHON-001) also supports that melatonin (10 ng/mL) blocks hydrogen peroxide-induced production of iNOS by suppressing the degradation of IκB-α and the translocation of NF-κB . However, Choi et al. demonstrated that the effect of melatonin in NF-κB is not that of reducing the degradation of IκB-α, but blocking the DNA binding activity of NF-κB p50 subunit in LPS-activated RAW264.7 cells . A study has found that melatonin inhibits p300 histone acetyltransferase (HAT) activity and the acetylation in NF-κB p50 subunit, which may result in the reduction in DNA binding activity of NF-κB . Shi et al. further demonstrated that melatonin treatment markedly inhibits the binding of NF-κB to COX-2 and iNOS promoter. This effect probably results from the reduction of p300 HAT induced-acetylation in NF-κB p50 .
In the in vivo studies, the effect of melatonin in the suppression of NF-κB action via inhibition of its translocation or binding activity has been identified [32,33,54]. The study presented by Kang et al. demonstrated that melatonin i.p. administration (10 mg/kg) attenuates the protein and mRNA expression levels of TNF-α, IL-6 and iNOS in the liver of SD rat with ischemia and reperfusion injury. They also observed that the translocation of NF-κB was reduced and the cytosolic level of IκB-α was decreased . Furthermore, the treatment dosage of melatonin may also critical to the anti-inflammatory effect. The study presented by Wang et al. demonstrated that melatonin treatment at pharmacological concentration (1 mM), but not at physiological concentration (1 nM), inhibits the activation of NF-κB in T98G and U251 glioma cells .
Generally, melatonin administration at pharmacological level suppresses the production of inflammatory cytokines and iNOS via inhibition of NF-κB. The underlying mechanisms may go through inhibition of NF-κB expression, reduction of IκB-α degradation and NF-κB translocation, or suppression of the DNA binding activity of NF-κB.
1.5. The Modulatory Effect of Melatonin on the Th1/2 Balance
Melatonin has been reported to exert immunomodulatory effects on Th1/2 development. The study reported by Garcia-Maurino et al. found that melatonin enhances the production of IL-2, IL-6, and IFN-γ in human circulating CD4 cells . It has been observed that the peak plasma levels of melatonin in healthy subjects coincide with a peak in the secretion of lipopolysaccharide-stimulated IFN-γ in whole blood . These data imply an association between IFN-γ production and melatonin secretion. Melatonin can also activate Th1 lymphocytes by increasing IL-12 production by APC .
By contrast, melatonin plays a role in the enhancement of Th2 immunity. Shaji et al. have reported that treatment of BALB/c mice with melatonin induces T cells to secrete IL-4 and downregulates the levels of IL-2 and IFN-γ . Some of these differences may be related to the different doses of melatonin used. Previous studies have demonstrated that treatment of mice with low-dose melatonin restores attenuated T cell activity  and increases Th1 cytokine levels . By contrast, high-dose (200 mg/kg) melatonin treatment significantly decreased the immunoglobulin (Ig)M-response to allogeneic stimulation and abrogated acute rejection of cardiac allografts in rats, while low-dose (20 mg/kg) melatonin increased the production of allospecific IgM antibodies . These observations suggest that melatonin may differentially modulate the immune responses in a dose-dependent manner in vitro and in vivo.
2. Overview of Autoimmune Diseases and Modulatory Effects of Melatonin on These Diseases
Autoimmune diseases affect approximately 5% of the population in Western countries. These diseases can be systemic, such as systemic lupus erythematosus (SLE), or organ-specific, such as type 1 diabetes mellitus (T1D). Autoimmune diseases are caused by the activation of immune cells, such as T or B cells, by antigens in the normal tissues. Activation of autoantigen-specific immune cells leads to subsequent damage to target tissues by these activated cells .
In the next section of this article, we will discuss the role and the modulatory effect of melatonin in several inflammatory autoimmune diseases including multiple sclerosis (MS), SLE, rheumatoid arthritis (RA), T1D, and inflammatory bowel disease (IBD).
2.1. Multiple Sclerosis
2.1.1. The Pathogenesis and Animal Model of MS
MS is the most prevalent inflammatory demyelinating disease of the central nervous system (CNS) in human adults . The prevalence varies from 60–200 per 100,000 in Northern Europe and North America to 6–20 per 100,000 in lower-risk areas. This disease results from the loss of the neuronal myelin sheath because of attack by autoantigen-specific immune cells, and usually manifests at between 20 and 40 years of age . Experimental autoimmune encephalomyelitis (EAE) is the most frequently used animal model of MS because of its clinical and histopathological similarities to MS . It can be induced in several species of animals by immunization with whole myelin proteins or specific myelin peptide epitopes, including myelin oligodendrocyte glycoprotein or myelin basic protein, emulsified in complete Freund’s adjuvant .
Both adaptive and innate immune cells are associated with the pathogenesis of MS. T cells and macrophages were observed to infiltrate the CNS lesions in animals with EAE . The adaptive immune CD4 T cells play a critical role in the initiation of the autoimmune process. Innate immune cells such as macrophages produce inflammatory cytokines under stimulation by CD4 T cells. The presence of proinflammatory cytokines in CNS contributes to the severe inflammation seen in EAE and results in damage to the myelin sheath and neurons. These cytokines also lead to the generation of reactive oxygen species in the affected sites. Indeed, markers of oxidative stress have been reported to be increased in the sera of MS patients [68–70] and in the CNS of rats with hyperacute EAE .
2.1.2. The Role of Melatonin in MS
An association between melatonin and MS has been suggested by several clinical observations. Sleep disruption is a frequent complaint in MS patients and contributes to daytime fatigue . Melamud et al. observed that MS patients excrete a subnormal proportion of 6-sulpahtoxymelatonin (a melatonin metabolite) in the urine at night, indicating a dysregulation of melatonin production or altered enzymatic metabolism of melatonin in MS patients, and may suggest melatonin may be involved in this disease . Shift work leads to disrupted circadian rhythms and sleep restriction, and a report published in 2011 found that shift work at a young age is associated with an increased risk for MS . These reports suggest that a dysregulation of physiological level of melatonin may contribute to the pathogenesis of MS.
2.1.3. The Modulatory Role of Melatonin in EAE
The application of melatonin for the treatment of MS has been examined in the EAE animal model of this disease. One study in EAE indicated that melatonin treatment (5 mg/kg for 15 days) inhibited the onset of disease and reduced the severity of clinical signs. This protective effect resulted from the suppression of intracellular adhesion molecule (ICAM)-1 production in the spinal cord . However, an earlier study demonstrated that inhibition of the immunoenhancing effects of melatonin by luzindole, a melatonin receptor antagonist, prevented the onset of EAE . Luzindole acts as a selective melatonin receptor antagonist, with a higher affinity for the MT2 receptor than for the MT1 receptor . Since both MT1 and MT2 are expressed on the cell surface of lymphocytes, this selective antagonist may trigger a complex effect in lymphocytes that could underlie the contrasting conclusions of these two animal studies.
2.2. Systemic Lupus Erythematosus
2.2.1. The Pathogenesis and Animal Model of SLE
SLE is an autoimmune disease resulting from damage to tissues by immune cells. This disease may manifest at any age and in either sex, but women are more frequently affected than men. SLE is characterized by overproduction of a variety of anti-nuclear autoantibodies. Common symptoms include malar (“butterfly”) rash, photosensitivity, nephritis, and arthritis .
The pathogenesis of SLE involves activation of autoreactive T cells that subsequently initiate the hyperactivity of B cells. The activation of B cells leads to polyclonal hypergammaglobulinemia and immune complex deposition. Either Th1 or Th2 immune responses can be elevated in this disease. The levels of Th1 cytokines such as IL-2 and IFN-γ, and of Th2 cytokines, mainly IL-4, are increased in patients affected by SLE . However, SLE is still considered a Th1-dominant disease . In addition, the inflammatory cytokines TNF-α and IL-6 also contribute to the disease, and the importance of the IL-23-Th17 axis has also been demonstrated .
2.2.2. The Dual Role of Melatonin in SLE Is Gender-Dependent in Animal Models
Observation of the serum melatonin level in MRL-Faslpr mice found that the circadian melatonin rhythm was uncoupled from the light/dark cycle . In the MRL-Faslpr mouse model of SLE, IL-10 deficiency exacerbates the development of disease, including a reduction in the survival rate, increased severity of glomerulonephritis and skin lesions, enhanced production of pathogenic IgG2a/2b antibodies and an increased population of IFN-γ-producing T cells . The results of this study strongly suggest a protective role of IL-10 in SLE. Thus, the effect of melatonin on the induction of IL-10 production may be beneficial for the prevention or therapy of SLE. In fact, Jimenez-Caliani et al. found that melatonin administration (30 mg/kg in drinking water for 1 month) reduced serum levels of autoantibodies, decreased the production of inflammatory cytokines, and increased the secretion of IL-10 in female MRL-Faslpr mice. By contrast, in male mice, melatonin treatment shifted the Th2 immune response to a Th1 pattern that displayed higher levels of inflammatory cytokines and autoantibodies . Their data indicated that administration of melatonin has a gender-dependent dichotomous effect in MRL-Faslpr mice in the early stages of disease. A later study presented by the same authors confirmed that this gender-dependent effect of melatonin in MRL-Faslpr mice is through modulation of sex hormones .
The application of melatonin treatment also has a beneficial effect in another animal model of SLE. Treatment of mice with pristane-induced lupus with various doses of melatonin (0.01, 0.1, 1.0 mg/kg) reduced the serum titers of anti-single-stranded DNA and anti-histone antibodies. Histopathological analysis showed that this treatment also reduced the renal injury, resulting in milder glomerular atrophy and less thickening of capillary walls. The secretion of IL-6 in splenic lymphocytes was also reduced in melatonin treated mice . The authors suggested that this beneficial effect in the pristane-induced lupus mouse model is through the regulation of cytokine disturbances. Wu et al. also showed that melatonin treatment (20 mg/kg, sc.) ameliorates murine membranous nephritis through its antioxidant, antiapoptotic, and immunomodulatory effects . The results of this study imply that melatonin treatment may also act to ameliorate nephritis in SLE. Based on these studies, melatonin treatment could be beneficial for therapy in SLE.
2.3. Rheumatoid Arthritis
2.3.1. Pathogenesis and Animal Model of RA
RA is a chronic inflammation of the joints characterized by progressive erosion of cartilage and bone that is associated with the formation of proliferated pannus. The most commonly used animal model of this disease is collagen-induced arthritis (CIA) in which immune cells, such as CD4 T cells and macrophages, infiltrate the joints of experimental animals and lead to the inflammation and damage of joints.
The pathogenesis of RA is associated with hyperplasia, increased vascularity, and infiltration of inflammatory immune cells to the synovial membrane of patients. Autoantigen-specific CD4 T cells are a major contributor to the initiation of this autoimmune response. Activated autoreactive CD4 T cells stimulate monocytes, macrophages, and synovial fibroblasts to produce inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, which drive inflammation in RA. CD4 T cells also stimulate B cells to generate immunoglobulins related to this disease, such as rheumatoid factor .
2.3.2. The Disease-Promoting Effect of Melatonin in RA
RA patients suffer from joint pain and morning stiffness. It has been suggested that this is associated with the influence of the hormonal effect of circadian rhythms. In RA patients, serum melatonin levels exhibit a wider plateau than in healthy people . The serum levels of proinflammatory cytokines, especially IL-6, exhibit a close association with stiffness and pain levels in patients with RA, in whom the peak serum levels of TNF-α and IL-6 occur at 6:00 am and 7:00 am, respectively . By contrast, these two cytokines reach peak values at 3:00 am and 6:00 am, respectively, in healthy people.
Androgens have been found to exert a protective effect against the development of RA . In the study presented by Valenti and Giusti, melatonin receptor was presented in the plasma membrane of isolated rat Leydig cells, and the secretion of testosterone in these cells was reduced in the presence of melatonin . This effect has been suggested to be the cause of the lower incidence of RA in men. A clinical trial of melatonin treatment in RA has been undertaken , in which RA patients received 10 mg melatonin at night in addition to ongoing medication. There was an increase in the erythrocyte sedimentation rate and neopterin concentrations in melatonin-treated patients, suggesting a proinflammatory effect of melatonin. However, there were no significant effects on clinical symptoms or on the concentrations of IL-1β, IL-6, and TNF-α in the serum of melatonin-treated patients.
2.3.3. Investigation of Melatonin in an Animal Model of RA
The influence of melatonin on the onset of RA has also been investigated in an animal model of this disease. An earlier study reported that constant darkness exaggerates the development of CIA in DBA/1 mice, implying a pathogenic role of melatonin in CIA . Hansson et al. demonstrated that DBA/1 mice injected subcutaneously with 1 mg/kg melatonin once daily showed exaggerated development of CIA via enhancement of T cell priming . In addition, pinealectomy ameliorates CIA in either DBA/1 or NFR/N mice . As melatonin is the major product of the pineal gland, this result suggests that unlike the other autoimmune diseases we discuss in this article, melatonin may have a promoting effect in the development of RA. Although one study found that melatonin possesses dose-dependent (from 1 to 100 μg/kg) prophylactic and therapeutic effects in an adjuvant-induced arthritis rat model , a recent study documented that melatonin treatment (10 mg/kg) increased the severity of CIA, probably via attenuation of the expression of cryptochrome 1. These contrasting observations may result from the different dosages or different models (DBA/1 mouse vs. rat) used in these studies. A study published in 2005 that used a CIA rat model and a lower dosage of melatonin treatment (30 μg/kg) demonstrated that melatonin had a proinflammatory effect and increased the severity of joint damage . Thus, these previous studies in animal models of RA suggest that melatonin trends to promote the development or increase the severity of RA.
2.4. Type 1 Diabetes Mellitus
2.4.1. Pathogenesis of T1D
T1D, also known as insulin-dependent diabetes mellitus (IDDM), results from the destruction of insulin-producing β cells in the pancreatic islets and has been identified as a T cell-mediated autoimmune disease . T1D is usually diagnosed in young people and is also called as juvenile-onset diabetes or childhood-onset diabetes. People with T1D have the classical phenotype (polydipsia, polyphagia, and polyuria) of diabetes mellitus resulting from hyperglycemia-induced osmotic dieresis and secondary thirst. This disease is characterized by hyperglycemia (resulting from abnormally increased gluconeogenesis and insufficient glucose disposal), ketosis (resulting from the accumulation of free fatty acids and their oxidation), insulitis (mononuclear cell infiltration of islets), and the presence of anti-islet antibodies (including anti-insulin antibodies (AIAs), IA-2 autoantibodies, and anti-glutamic acid decarboxylase (GAD) antibodies).
2.4.2. Pathogenesis of Autoimmune Diabetes in NOD Mice
The NOD mouse strain spontaneously develops T cell-dependent β cell destruction resembling human T1D, and serves as an animal model for this autoimmune disease . This mouse strain exhibits a sexual dimorphism not seen in humans, where 80%–90% of female mice, but only 40%–50% of male mice, develop diabetes by the age of 30 weeks . Treatment of female NOD mice with androgen at 8 weeks of age prevented islet destruction and diabetes without eliminating the islet inflammatory cells . These observations indicate an association between the endocrine and immune systems.
It has been well characterized that an imbalance between Th1 and Th2 responses predisposes NOD mice to developing autoimmune diabetes [104,105]. The CD4 T cells in NOD mice show a Th1-cell-dominant phenotype, which manifests as increased IFN-γ and decreased IL-4 production by activated CD4 T cells of NOD mice . It has been identified that Th1 cells play a pathogenic role in initiation of the disease process: treatment of NOD mice with neutralizing antibodies against IFN-γ can effectively prevent the onset of diabetes , and adoptive transfer of IFN-γ-depleted cells can prevent diabetes in NOD mice . In addition, administration of typical Th2 cytokines, IL-4 or IL-10, can prevent or delay the onset of autoimmune diabetes [109,110].
2.4.3. The Influence of Melatonin on the Insulin Production of Pancreatic β Cells
The expression of melatonin receptors has been detected in pancreatic β cells . Thus, melatonin treatment may also influence the physiological activities of β cells such as insulin production. Indeed, a study has demonstrated that the synthesis of melatonin was increased in an animal model of streptozotocin-induced T1D . Moreover, an influence of melatonin on insulin secretion has also been documented. Stumpf et al. reported that melatonin treatment inhibits insulin secretion in rat INS1 insulinoma β cells . However, Ramracheya et al. demonstrated that melatonin may have a species-specific effect ; melatonin treatment inhibited glucose-stimulated insulin secretion by mouse insulinoma β cells (MIN6), but stimulated insulin secretion in human islets. Another possibility to explain these differences may be the differences between insulinoma β-cell lines and primary isolated islets. The insulinoma β cell lines are composed of a single cell population and primary isolated islets contain not only β cells, but also α-cells, δ-cells, and Schwann cells. The different composition of β cell lines and islets may explain the diverse results of these studies.
2.4.4. Modulatory Role of Melatonin in T1D
T1D has been considered a Th1-cell-dominant autoimmune disease. Thus, the effect of melatonin in shifting the immune response toward Th2 cells may be beneficial for disease modulation. Furthermore, it is well documented that proinflammatory cytokines such as TNF-α and IFN-γ contribute to β cell destruction. The immune cells infiltrating in the islets, such as macrophages and CD8 T cells, secrete the proinflammatory cytokines TNF-α and IL-1β, which enhance inflammation and induce apoptosis of β cells . Therefore, the anti-inflammatory effect of melatonin may also be beneficial for the inhibition of disease onset or improvement of the survival of islet grafts transplanted for T1D therapy. Indeed, a study has shown that melatonin treatment prolongs the lifespan of NOD mice whereas neonatal pinealectomy accelerates the development of autoimmune diabetes .
2.4.5. The Application of Melatonin on Islet Transplantation
Islet transplantation has been established as a potential therapeutic strategy for T1D that could provide nearly perfect blood glucose monitoring and modulation. Recurrent autoimmunity plays a crucial role in islet graft destruction in NOD mice [116,117] and in human islet transplantation [118,119]. Moreover, destruction of grafts by autoimmune recurrence often takes place earlier than allogeneic graft rejection . Suppression of autoimmune recurrence and allograft rejection is therefore a critical issue in islet transplantation.
The effects of melatonin in organ transplantation have also been explored. Several studies indicated that melatonin treatment prolongs graft survival in solid organ transplantation. Sapmaz et al. demonstrated that a single i.p. melatonin injection after autologous ovary transplantation attenuated ovarian tissue necrosis following engraftment. In addition, high-dose (200 mg/kg) melatonin treatment prolonged the survival of cardiac allografts in rats by reducing lymphocyte proliferation . Our previous work showed that high-dose melatonin treatment effectively prolonged the survival of islet grafts in diabetic NOD recipients , and showed increased expression of the immunosuppressive cytokine IL-10 and an increased population of IL-10-producing CD4 T cells in the spleen of melatonin-treated NOD mice. These results may in part explain the reduced proliferative ability of T cells and the decreased population of Th1 cells in mice treated with high-dose melatonin, and are consistent with a previous study by Raghavendra et al. showing that melatonin treatment increases the amount of IL-10 in serum . In the same report, this group also demonstrated that melatonin treatment increased the production of IL-10 by anti-CD3-stimulated T cells in the presence of APC . It has also been reported that IL-10 treatment prolongs the survival of grafts in islet transplantation. Moreover, Zhang et al. demonstrated that adeno-associated virus-mediated IL-10 gene transfer inhibits autoimmune recurrence in syngeneic islet cell transplantation in NOD mice. Kim et al. also reported that transduction of IL-10 into islets combined with subtherapeutic doses of cyclosporine significantly prolonged islet allograft survival. Our study confirmed that melatonin treatment elicits a protective effect in islet transplantation of NOD mice via IL-10. These results support the concept that melatonin treatment may be of benefit in either syngeneic or allogeneic islet transplantation for the treatment of T1D.
2.5. Inflammatory Bowel Disease
2.5.1. Pathogenesis of IBD
Crohn’s disease and ulcerative colitis are immunologically mediated disorders collectively referred to as IBD. They are characterized by idiopathic, chronic, and relapsing inflammation in the small and large intestines. However, these two types of colitis also exhibit several different features. For example, the inflammation in Crohn’s disease is usually transmural, whereas in ulcerative colitis it is typically confined to the mucosa. Crohn’s disease usually affects the ileum and colon, but also other regions of the intestine, in a discontinuous pattern. By contrast, ulcerative colitis affects the rectum and part of or the entire colon with an uninterrupted pattern . The most frequently used animal models for this disease are chemically induced colitis in rats or genetically modified in mice. The chemically induced models include trinitrobenzene sulfonic acid (TNBS)-induced colitis, dextran sulfate sodium (DSS) colitis and oxazolone colitis. The genetically modified models include IL-10-deficiency colitis, T-bet transgenic mice, and STAT4 transgenic mice .
Accumulation of immune cells in the intestinal tissues of patients is one characteristic of IBD. The cells infiltrating the lamina propria include innate and adaptive immune cells, such as neutrophils, macrophages, dendritic cells, B cells, and T cells. Activation of these immune cells in the intestinal mucosa induces inflammatory responses and elevates the local levels of cytokines including TNF-α, IL-1β, IL-6, and IFN-γ . Effector T cells play a critical role in the pathogenesis of IBD. Th1 and Th2 cells are involved in the development of Crohn’s disease and ulcerative colitis, respectively . T cells isolated from the lamina propria lesions of Crohn’s disease produce increased amounts of IFN-γ, indicating a Th1 phenotype. By contrast, T cells from ulcerative colitis produce increased amounts of IL-5, suggesting an atypical Th2 inflammation . In addition, recent genetic association analysis studies of IBD patients or investigations in murine models of this disease have demonstrated that the IL-23-Th17 pathway also plays an important role in the pathogenesis of IBD [130–133].
2.5.2. The Therapeutic Potential of Melatonin Administration in IBD
The effect of melatonin treatment in animal models of IBD has been investigated. A study in 1995 showed that daily i.p. melatonin administration (150 μg/kg) reduced the severity of DSS colitis in mice . It was also reported that pretreatment of rats with melatonin (5 mg/kg and 10 mg/kg) reduced the disease scores for colonic inflammation induced by acetic acid . This result is consistent with a previous study documenting that melatonin treatment at the same dose significantly ameliorated colonic injury in rat models of acetic acid-induced colitis and TNBS-induced colitis . Cuzzocrea et al. also showed that melatonin treatment (15 mg/kg daily, i.p.) significantly reduced the appearance of diarrhea and the loss of body weight in rats with dinitrobenzene sulfonic acid-induced colitis . This therapeutic effect is mediated by decreasing the production of TNF-α, reducing the activation of NF-κB, decreasing the expression and activity of matrix metalloproteinase (MMP)-9 and -2, and the antiapoptotic effect of melatonin [138,139]. The effect of melatonin administration has also been tested in a TNBS-induced colitis rat model. Treatment with10 mg/kg/day i.p. melatonin injection for 15 days significantly decreased the pathological disease scores in TNBS-treated rats and reduced the expression of NF-κB and the activities of myeloperoxidase, malondialdehyde, and caspase-3 in colon tissue. By contrast, the colonic level of glutathione was increased by this treatment. The results of this study suggest that melatonin administration is beneficial for IBD via its antioxidant, anti-apoptotic, and antiinflammatory effects [140–142]. This result has also confirmed by another study in the same year, where acute administration of 2 mg/kg melatonin significantly reduced the severity of colitis in TNBS-treated rats although long-term treatment had a negative influence on disease outcome .
2.5.3. Clinical Trial of Melatonin Treatment in IBD
The application of melatonin in IBD patients has also been documented. Chojnacki et al. have evaluated adjuvant treatment with melatonin in ulcerative colitis patients. This strategy kept the treated patients in remission for the 12 months of their observation period. The C-reactive protein concentration in the blood of melatonin-treated patients remained within the normal range during the course of the study, and the decrease in hemoglobin concentration in melatonin-treated patients was less than that in placebo controls . These results indicate that adjuvant melatonin therapy should be helpful in sustaining remission in ulcerative colitis patients.
3. The Future Application of Melatonin Treatment in Autoimmune Diseases
Melatonin has been demonstrated to possess multiple activities, including antioxidation, anti-inflammatory, and immunomodulatory effects. Therefore, this natural pineal gland product is highly attractive to investigators of autoimmune diseases. For example, IL-10 is one of the most extensively investigated and promising candidates for the treatment of autoimmune diseases [145,146], and IL-10-deficient NOD mice show accelerated development of diabetes under cyclophosphamide treatment . However, treatment of NOD mice with recombinant human IL-10 prevents the onset of T1D . IL-10-deficient mice spontaneously develop chronic enterocolitis , which can be prevented by transferring IL-10-producing CD4 T cells . Given the ability of melatonin to elicit IL-10 production and increase the number of IL-10-producing CD4 T cells [150–152], melatonin treatment might be applicable for the therapy of autoimmune diseases such as MS, SLE, and IBD.
One major concern in these studies we discussed in this review is the different routes of melatonin administration. In oral administration, melatonin is first metabolized by liver. By contrast, intraperitoneal or subcutaneous injection may bypass hepatic metabolism in the beginning of melatonin treatment. An earlier study presented by Kennaway and Seamark showed that subcutaneous injection of melatonin quickly leads to a high plasma level in sheep, but it declines rapidly. By contrast, oral administration leads to a lower but constant plasma melatonin level . DeMuro et al. demonstrated that intravenous injection of melatonin can reach a much higher serum melatonin concentration in humans when compared to oral administration. However, the half-life of melatonin in the serum showed no significant difference between these two different routes of administration . These results suggest that the routes of melatonin administration will influence the peak plasma level of melatonin but not the half-life of melatonin. Therefore, administration of melatonin by intravenous or subcutaneous injection will be suitable in the clinical application of melatonin treatment for higher dosages.
Another concern in the application of melatonin treatment for autoimmune diseases is the high doses used in the experiments with animal models. However, melatonin exhibits a high level of safety in clinical trials. In a clinical trial in patients with amyotrophic lateral sclerosis, a daily oral dose of 30–60 mg of melatonin was well tolerated and generated no side effects . In a later clinical trial, patients who received daily rectal melatonin treatment at a higher dose (300 mg per day) also did not show any complications . A recent report also demonstrated that treatment of patients undergoing major aortic surgery with up to 60 mg intravenous melatonin during surgery was safe and without complications . Therefore, application of a high pharmacological dose of melatonin in the therapy of autoimmune diseases should be acceptable. However, the treatment doses used in some of the animal studies are higher than the treatment of melatonin used in human clinical trials. Thus, the appropriate doses used in clinical application for inflammatory autoimmune diseases still need to be examined.
4. Concluding Remarks
Melatonin therapy has been studied in several animal models of autoimmune disease and evaluated in patients with clinical autoimmune disease (Figure 1). For most of the autoimmune diseases discussed in this article except RA, melatonin treatment reduced the severity of disease in animal models (Table 1) and some clinical trials [93,144]. These observations suggest the importance of endogenous melatonin in the development of autoimmune disease and the possibility of exogenous melatonin treatment of human autoimmune diseases.
This work was supported by the National Science Council, Taiwan (NSC99-2320-B-016- 001-MY3, NSC101-2321-B-016-002 to H.-K. Sytwu and NSC101-2320-B-016-016 to G.-J. Lin), Tri-service General Hospital (TSGH-C102-007-009-S01) and in part by the C.Y. Foundation for Advancement of Education, Sciences and Medicine.
|EAE||experimental autoimmune encephalomyelitis|
|DSS||dextran sodium sulphate|
|DNBS||dinitrobenzene sulfonic acid|
|TNBS||trinitrobenzene sulfonic acid|
Conflict of Interest
The authors declare no conflict of interest.
- Tan, D.X.; Manchester, L.C.; Hardeland, R.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Melatonin: A hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal Res. 2003, 34, 75–78.
- Reiter, R.J. The melatonin rhythm: Both a clock and a calendar. Experientia 1993, 49, 654–664.
- Malpaux, B.; Migaud, M.; Tricoire, H.; Chemineau, P. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J. Biol. Rhythms 2001, 16, 336–347.
- Maldonado, M.D.; Murillo-Cabezas, F.; Terron, M.P.; Flores, L.J.; Tan, D.X.; Manchester, L.C.; Reiter, R.J. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J. Pineal Res 2007, 42, 1–11.
- Peyrot, F.; Ducrocq, C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J. Pineal Res 2008, 45, 235–246.
- Reiter, R.J.; Tan, D.X.; Terron, M.P.; Flores, L.J.; Czarnocki, Z. Melatonin and its metabolites: New findings regarding their production and their radical scavenging actions. Acta Biochim. Pol 2007, 54, 1–9.
- Reiter, R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev 1991, 12, 151–180.
- Tan, D.X.; Manchester, L.C.; Reiter, R.J.; Plummer, B.F.; Hardies, L.J.; Weintraub, S.T.; Vijayalaxmi Shepherd, A.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998, 253, 614–620.
- Bubenik, G.A. Thirty four years since the discovery of gastrointestinal melatonin. J. Physiol. Pharmacol 2008, 59, S33–S51.
- Jaworek, J.; Brzozowski, T.; Konturek, S.J. Melatonin as an organoprotector in the stomach and the pancreas. J. Pineal Res 2005, 38, 73–83.
- Stefulj, J.; Hortner, M.; Ghosh, M.; Schauenstein, K.; Rinner, I.; Wolfler, A.; Semmler, J.; Liebmann, P.M. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J. Pineal Res 2001, 30, 243–247.
- Gomez-Corvera, A.; Cerrillo, I.; Molinero, P.; Naranjo, M.C.; Lardone, P.J.; Sanchez-Hidalgo, M.; Carrascosa-Salmoral, M.P.; Medrano-Campillo, P.; Guerrero, J.M.; Rubio, A. Evidence of immune system melatonin production by two pineal melatonin deficient mice, C57BL/6 and Swiss strains. J. Pineal Res 2009, 47, 15–22.
- Carrillo-Vico, A.; Calvo, J.R.; Abreu, P.; Lardone, P.J.; Garcia-Maurino, S.; Reiter, R.J.; Guerrero, J.M. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: Possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004, 18, 537–539.
- Conti, A.; Conconi, S.; Hertens, E.; Skwarlo-Sonta, K.; Markowska, M.; Maestroni, J.M. Evidence for melatonin synthesis in mouse and human bone marrow cells. J. Pineal Res 2000, 28, 193–202.
- Naranjo, M.C.; Guerrero, J.M.; Rubio, A.; Lardone, P.J.; Carrillo-Vico, A.; Carrascosa-Salmoral, M.P.; Jimenez-Jorge, S.; Arellano, M.V.; Leal-Noval, S.R.; Leal, M.; et al. Melatonin biosynthesis in the thymus of humans and rats. Cell. Mol. Life Sci 2007, 64, 781–790.
- Carrillo-Vico, A.; Guerrero, J.M.; Lardone, P.J.; Reiter, R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27, 189–200.
- Garcia-Maurino, S.; Gonzalez-Haba, M.G.; Calvo, J.R.; Rafii-El-Idrissi, M.; Sanchez-Margalet, V.; Goberna, R.; Guerrero, J.M. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol 1997, 159, 574–581.
- Pozo, D.; Delgado, M.; Fernandez-Santos, J.M.; Calvo, J.R.; Gomariz, R.P.; Martin-Lacave, I.; Ortiz, G.G.; Guerrero, J.M. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 1997, 11, 466–473.
- Pioli, C.; Caroleo, M.C.; Nistico, G.; Doria, G. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int. J. Immunopharmacol 1993, 15, 463–468.
- Currier, N.L.; Sun, L.Z.; Miller, S.C. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. J. Neuroimmunol 2000, 104, 101–108.
- Garcia-Maurino, S.; Gonzalez-Haba, M.G.; Calvo, J.R.; Goberna, R.; Guerrero, J.M. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J. Neuroimmunol 1998, 92, 76–84.
- Raghavendra, V.; Singh, V.; Kulkarni, S.K.; Agrewala, J.N. Melatonin enhances Th2 cell mediated immune responses: Lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol. Cell. Biochem 2001, 221, 57–62.
- Shaji, A.V.; Kulkarni, S.K.; Agrewala, J.N. Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin-specific T cells. Clin. Exp. Immunol 1998, 111, 181–185.
- Raghavendra, V.; Singh, V.; Shaji, A.V.; Vohra, H.; Kulkarni, S.K.; Agrewala, J.N. Melatonin provides signal 3 to unprimed CD4(+) T cells but failed to stimulate LPS primed B cells. Clin. Exp. Immunol 2001, 124, 414–422.
- Majewska, M.; Zajac, K.; Zemelka, M.; Szczepanik, M. Influence of melatonin and its precursor L-tryptophan on Th1 dependent contact hypersensitivity. J. Physiol. Pharmacol 2007, 58, S125–S132.
- Konakchieva, R.; Kyurkchiev, S.; Kehayov, I.; Taushanova, P.; Kanchev, L. Selective effect of methoxyindoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J. Neuroimmunol 1995, 63, 125–132.
- Wang, H.; Wei, W.; Wang, N.P.; Gui, S.Y.; Wu, L.; Sun, W.Y.; Xu, S.Y. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci 2005, 77, 1902–1915.
- Lahiri, S.; Singh, P.; Singh, S.; Rasheed, N.; Palit, G.; Pant, K.K. Melatonin protects against experimental reflux esophagitis. J. Pineal Res 2009, 46, 207–213.
- Korhonen, R.; Lahti, A.; Kankaanranta, H.; Moilanen, E. Nitric oxide production and signaling in inflammation. Curr. Drug Targets 2005, 4, 471–479.
- Szczepanik, M. Melatonin and its influence on immune system. J. Physiol. Pharmacol 2007, 58, S115–S124.
- Crespo, E.; Macias, M.; Pozo, D.; Escames, G.; Martin, M.; Vives, F.; Guerrero, J.M.; Acuna-Castroviejo, D. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999, 13, 1537–1546.
- Jung, K.H.; Hong, S.W.; Zheng, H.M.; Lee, D.H.; Hong, S.S. Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J. Pineal Res 2009, 47, 173–183.
- Veneroso, C.; Tunon, M.J.; Gonzalez-Gallego, J.; Collado, P.S. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J. Pineal Res 2009, 47, 184–191.
- Lopez, L.C.; Escames, G.; Tapias, V.; Utrilla, P.; Leon, J.; Acuna-Castroviejo, D. Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: Its relation with mitochondrial dysfunction and prevention by melatonin. Int. J. Biochem. Cell. Biol 2006, 38, 267–278.
- Escames, G.; Lopez, L.C.; Ortiz, F.; Lopez, A.; Garcia, J.A.; Ros, E.; Acuna-Castroviejo, D. Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J 2007, 274, 2135–2147.
- Lowes, D.A.; Almawash, A.M.; Webster, N.R.; Reid, V.L.; Galley, H.F. Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis. Br. J. Anaesth 2011, 107, 193–201.
- Lowes, D.A.; Webster, N.R.; Murphy, M.P.; Galley, H.F. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br. J. Anaesth 2013, 110, 472–480.
- Tak, P.P.; Firestein, G.S. NF-κB: A key role in inflammatory diseases. J. Clin. Invest 2001, 107, 7–11.
- Chuang, J.I.; Mohan, N.; Meltz, M.L.; Reiter, R.J. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell. Biol. Int 1996, 20, 687–692.
- Bertuglia, S.; Marchiafava, P.L.; Colantuoni, A. Melatonin prevents ischemia reperfusion injury in hamster cheek pouch microcirculation. Cardiovasc. Res 1996, 31, 947–952.
- Sewerynek, E.; Reiter, R.J.; Melchiorri, D.; Ortiz, G.G.; Lewinski, A. Oxidative damage in the liver induced by ischemia-reperfusion: Protection by melatonin. Hepatogastroenterology 1996, 43, 898–905.
- Reiter, R.J.; Calvo, J.R.; Karbownik, M.; Qi, W.; Tan, D.X. Melatonin and its relation to the immune system and inflammation. Ann. N. Y. Acad. Sci 2000, 917, 376–86.
- Gilad, E.; Wong, H.R.; Zingarelli, B.; Virag, L.; O’Connor, M.; Salzman, A.L.; Szabo, C. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: Role of inhibition of NF-κB activation. FASEB J 1998, 12, 685–693.
- Li, Z.; Nickkholgh, A.; Yi, X.; Bruns, H.; Gross, M.L.; Hoffmann, K.; Mohr, E.; Zorn, M.; Buchler, M.W.; Schemmer, P. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-κB and apoptosis after experimental kidney transplantation. J. Pineal Res 2009, 46, 365–372.
- Ozbek, E.; Ilbey, Y.O.; Ozbek, M.; Simsek, A.; Cekmen, M.; Somay, A. Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-κB expression. J. Endourol 2009, 23, 1165–1173.
- Pascua, P.; Camello-Almaraz, C.; Camello, P.J.; Martin-Cano, F.E.; Vara, E.; Fernandez-Tresguerres, J.A.; Pozo, M.J. Melatonin, and to a lesser extent growth hormone, restores colonic smooth muscle physiology in old rats. J. Pineal Res 2011, 51, 405–415.
- Yip, H.K.; Chang, Y.C.; Wallace, C.G.; Chang, L.T.; Tsai, T.H.; Chen, Y.L.; Chang, H.W.; Leu, S.; Zhen, Y.Y.; Tsai, C.Y.; et al. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J. Pineal Res 2013, 54, 207–221.
- Qin, W.; Lu, W.; Li, H.; Yuan, X.; Li, B.; Zhang, Q.; Xiu, R. Melatonin inhibits IL1beta-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF-κB activation. J. Endocrinol 2012, 214, 145–153.
- Xia, M.Z.; Liang, Y.L.; Wang, H.; Chen, X.; Huang, Y.Y.; Zhang, Z.H.; Chen, Y.H.; Zhang, C.; Zhao, M.; Xu, D.X.; et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J. Pineal Res 2012, 53, 325–334.
- Lim, H.D.; Kim, Y.S.; Ko, S.H.; Yoon, I.J.; Cho, S.G.; Chun, Y.H.; Choi, B.J.; Kim, E.C. Cytoprotective and anti-inflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J. Pineal Res 2012, 53, 225–237.
- Choi, E.Y.; Jin, J.Y.; Lee, J.Y.; Choi, J.I.; Choi, I.S.; Kim, S.J. Melatonin inhibits prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-6 in murine macrophages by suppressing NF-κB and STAT1 activity. J. Pineal Res. 2011, 50, 197–206.
- Wang, J.; Xiao, X.; Zhang, Y.; Shi, D.; Chen, W.; Fu, L.; Liu, L.; Xie, F.; Kang, T.; Huang, W.; et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res 2012, 53, 77–90.
- Shi, D.; Xiao, X.; Wang, J.; Liu, L.; Chen, W.; Fu, L.; Xie, F.; Huang, W.; Deng, W. Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-κB, c/EBPbeta, and p300 signaling. J. Pineal Res 2012, 53, 154–165.
- Marino, A.; Di Paola, R.; Crisafulli, C.; Mazzon, E.; Morabito, R.; Paterniti, I.; Galuppo, M.; Genovese, T.; La Spada, G.; Cuzzocrea, S. Protective effect of melatonin against the inflammatory response elicited by crude venom from isolated nematocysts of Pelagia noctiluca (Cnidaria, Scyphozoa). J. Pineal Res 2009, 47, 56–69.
- Kang, J.W.; Koh, E.J.; Lee, S.M. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J. Pineal Res 2011, 50, 403–411.
- Wang, J.; Hao, H.; Yao, L.; Zhang, X.; Zhao, S.; Ling, E.A.; Hao, A.; Li, G. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J. Pineal Res 2012, 53, 180–187.
- Petrovsky, N.; Harrison, L.C. Diurnal rhythmicity of human cytokine production: A dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J. Immunol 1997, 158, 5163–5168.
- Garcia-Maurino, S.; Pozo, D.; Carrillo-Vico, A.; Calvo, J.R.; Guerrero, J.M. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 1999, 65, 2143–2150.
- Maestroni, G.J.; Conti, A.; Pierpaoli, W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann. N. Y. Acad. Sci 1988, 521, 140–148.
- Inserra, P.; Zhang, Z.; Ardestani, S.K.; Araghi-Niknam, M.; Liang, B.; Jiang, S.; Shaw, D.; Molitor, M.; Elliott, K.; Watson, R.R. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc. Soc. Exp. Biol. Med 1998, 218, 76–82.
- Jung, F.J.; Yang, L.; Harter, L.; Inci, I.; Schneiter, D.; Lardinois, D.; Keel, M.; Weder, W.; Korom, S. Melatonin in vivo prolongs cardiac allograft survival in rats. J. Pineal Res 2004, 37, 36–41.
- Davidson, A.; Diamond, B. Autoimmune diseases. N. Engl. J. Med 2001, 345, 340–350.
- Steinman, L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299–302.
- Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol 2005, 23, 683–747.
- Ercolini, A.M.; Miller, S.D. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J. Immunol 2006, 176, 3293–3298.
- Martin, R.; McFarland, H.F.; McFarlin, D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol 1992, 10, 153–187.
- Sobel, R.A.; Blanchette, B.W.; Bhan, A.K.; Colvin, R.B. The immunopathology of experimental allergic encephalomyelitis. I. Quantitative analysis of inflammatory cells in situ. J. Immunol 1984, 132, 2393–2401.
- Besler, H.T.; Comoglu, S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr. Neurosci 2003, 6, 189–196.
- Glabinski, A.; Tawsek, N.S.; Bartosz, G. Increased generation of superoxide radicals in the blood of MS patients. Acta Neurol. Scand 1993, 88, 174–177.
- Hunter, M.I.; Nlemadim, B.C.; Davidson, D.L. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem. Res 1985, 10, 1645–1652.
- MacMicking, J.D.; Willenborg, D.O.; Weidemann, M.J.; Rockett, K.A.; Cowden, W.B. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: Enhancement by the soluble products of encephalitogenic T cells. J. Exp. Med 1992, 176, 303–307.
- Brass, S.D.; Duquette, P.; Proulx-Therrien, J.; Auerbach, S. Sleep disorders in patients with multiple sclerosis. Sleep. Med. Rev 2010, 14, 121–129.
- Melamud, L.; Golan, D.; Luboshitzky, R.; Lavi, I.; Miller, A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J. Neurol. Sci 2012, 314, 37–40.
- Hedstrom, A.K.; Akerstedt, T.; Hillert, J.; Olsson, T.; Alfredsson, L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann. Neurol 2011, 70, 733–741.
- Kang, J.C.; Ahn, M.; Kim, Y.S.; Moon, C.; Lee, Y.; Wie, M.B.; Lee, Y.J.; Shin, T. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J. Vet. Sci 2001, 2, 85–89.
- Constantinescu, C.S.; Hilliard, B.; Ventura, E.; Rostami, A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 1997, 65, 190–194.
- Dubocovich, M.L.; Yun, K.; Al-Ghoul, W.M.; Benloucif, S.; Masana, M.I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998, 12, 1211–1220.
- Tsokos, G.C. Systemic lupus erythematosus. N. Engl. J. Med 2011, 365, 2110–2121.
- Kidd, P. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev 2003, 8, 223–246.
- Hayashi, T. Therapeutic strategies for SLE involving cytokines: Mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J. Biomed. Biotechnol. 2010, 2010, doi:10.1155/2010/461641.
- Wong, C.K.; Lit, L.C.; Tam, L.S.; Li, E.K.; Wong, P.T.; Lam, C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol 2008, 127, 385–393.
- Lechner, O.; Dietrich, H.; Oliveira dos Santos, A.; Wiegers, G.J.; Schwarz, S.; Harbutz, M.; Herold, M.; Wick, G. Altered circadian rhythms of the stress hormone and melatonin response in lupus-prone MRL/MP-fas(Ipr) mice. J. Autoimmun 2000, 14, 325–333.
- Yin, Z.; Bahtiyar, G.; Zhang, N.; Liu, L.; Zhu, P.; Robert, M.E.; McNiff, J.; Madaio, M.P.; Craft, J. IL-10 regulates murine lupus. J. Immunol 2002, 169, 2148–2155.
- Jimenez-Caliani, A.J.; Jimenez-Jorge, S.; Molinero, P.; Fernandez-Santos, J.M.; Martin-Lacave, I.; Rubio, A.; Guerrero, J.M.; Osuna, C. Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: It ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 2006, 147, 1717–1724.
- Jimenez-Caliani, A.J.; Jimenez-Jorge, S.; Molinero, P.; Rubio, A.; Guerrero, J.M.; Osuna, C. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus. J. Pineal Res 2008, 45, 204–211.
- Zhou, L.L.; Wei, W.; Si, J.F.; Yuan, D.P. Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm. 2010, doi:10.1155/2010/951210.
- Wu, C.C.; Lu, K.C.; Lin, G.J.; Hsieh, H.Y.; Chu, P.; Lin, S.H.; Sytwu, H.K. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. J. Pineal Res 2012, 52, 460–469.
- Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med 2001, 344, 907–916.
- Sulli, A.; Maestroni, G.J.; Villaggio, B.; Hertens, E.; Craviotto, C.; Pizzorni, C.; Briata, M.; Seriolo, B.; Cutolo, M. Melatonin serum levels in rheumatoid arthritis. Ann. N. Y. Acad. Sci 2002, 966, 276–283.
- Cutolo, M.; Straub, R.H. Circadian rhythms in arthritis: Hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev 2008, 7, 223–228.
- Cutolo, M.; Balleari, E.; Giusti, M.; Monachesi, M.; Accardo, S. Sex hormone status of male patients with rheumatoid arthritis: Evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum 1988, 31, 1314–1317.
- Valenti, S.; Giusti, M. Melatonin participates in the control of testosterone secretion from rat testis: An overview of our experience. Ann. N. Y. Acad. Sci 2002, 966, 284–289.
- Forrest, C.M.; Mackay, G.M.; Stoy, N.; Stone, T.W.; Darlington, L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol 2007, 64, 517–526.
- Hansson, I.; Holmdahl, R.; Mattsson, R. Constant darkness enhances autoimmunity to type II collagen and exaggerates development of collagen-induced arthritis in DBA/1 mice. J. Neuroimmunol 1990, 27, 79–84.
- Hansson, I.; Holmdahl, R.; Mattsson, R. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J. Neuroimmunol. 1992, 39, 23–30.
- Hansson, I.; Holmdahl, R.; Mattsson, R. Pinealectomy ameliorates collagen II-induced arthritis in mice. Clin. Exp. Immunol 1993, 92, 432–436.
- Chen, Q.; Wei, W. Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat. Int. Immunopharmacol 2002, 2, 1443–1449.
- Bang, J.; Chang, H.W.; Jung, H.R.; Cho, C.H.; Hur, J.A.; Lee, S.I.; Choi, T.H.; Kim, S.H.; Ha, E. Melatonin attenuates clock gene cryptochrome1, which may aggravate mouse anti-type II collagen antibody-induced arthritis. Rheumatol. Int 2012, 32, 379–385.
- Jimenez-Caliani, A.J.; Jimenez-Jorge, S.; Molinero, P.; Guerrero, J.M.; Fernandez-Santos, J.M.; Martin-Lacave, I.; Osuna, C. Dual effect of melatonin as proinflammatory and antioxidant in collagen-induced arthritis in rats. J. Pineal Res 2005, 38, 93–99.
- Kawasaki, E.; Abiru, N.; Eguchi, K. Prevention of type 1 diabetes: From the view point of beta cell damage. Diabetes Res. Clin. Pract 2004, 66, S27–S32.
- Aoki, C.A.; Borchers, A.T.; Ridgway, W.M.; Keen, C.L.; Ansari, A.A.; Gershwin, M.E. NOD mice and autoimmunity. Autoimmun. Rev 2005, 4, 373–379.
- Wicker, L.S.; Todd, J.A.; Peterson, L.B. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol 1995, 13, 179–200.
- Fox, H.S. Androgen treatment prevents diabetes in nonobese diabetic mice. J. Exp. Med 1992, 175, 1409–1412.
- Liblau, R.S.; Singer, S.M.; McDevitt, H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 1995, 16, 34–38.
- Hung, J.T.; Liao, J.H.; Lin, Y.C.; Chang, H.Y.; Wu, S.F.; Chang, T.H.; Kung, J.T.; Hsieh, S.L.; McDevitt, H.; Sytwu, H.K. Immunopathogenic role of TH1 cells in autoimmune diabetes: Evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J. Autoimmun 2005, 25, 181–192.
- Koarada, S.; Wu, Y.; Olshansky, G.; Ridgway, W.M. Increased nonobese diabetic Th1:Th2 (IFN-gamma:IL-4) ratio is CD4+ T cell intrinsic and independent of APC genetic background. J. Immunol 2002, 169, 6580–6587.
- Debray-Sachs, M.; Carnaud, C.; Boitard, C.; Cohen, H.; Gresser, I.; Bedossa, P.; Bach, J.F. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun 1991, 4, 237–248.
- Campbell, I.L.; Kay, T.W.; Oxbrow, L.; Harrison, L.C. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest 1991, 87, 739–742.
- Cameron, M.J.; Arreaza, G.A.; Zucker, P.; Chensue, S.W.; Strieter, R.M.; Chakrabarti, S.; Delovitch, T.L. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol 1997, 159, 4686–4692.
- Pennline, K.J.; Roque-Gaffney, E.; Monahan, M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol 1994, 71, 169–175.
- Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res 2008, 44, 26–40.
- Peschke, E.; Wolgast, S.; Bazwinsky, I.; Ponicke, K.; Muhlbauer, E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J. Pineal Res 2008, 45, 439–448.
- Stumpf, I.; Muhlbauer, E.; Peschke, E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J. Pineal Res 2008, 45, 318–327.
- Ramracheya, R.D.; Muller, D.S.; Squires, P.E.; Brereton, H.; Sugden, D.; Huang, G.C.; Amiel, S.A.; Jones, P.M.; Persaud, S.J. Function and expression of melatonin receptors on human pancreatic islets. J. Pineal Res 2008, 44, 273–279.
- Conti, A.; Maestroni, G.J. Role of the pineal gland and melatonin in the development of autoimmune diabetes in non-obese diabetic mice. J. Pineal Res 1996, 20, 164–172.
- Okitsu, T.; Bartlett, S.T.; Hadley, G.A.; Drachenberg, C.B.; Farney, A.C. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am. J. Transplant 2001, 1, 138–145.
- Young, H.Y.; Zucker, P.; Flavell, R.A.; Jevnikar, A.M.; Singh, B. Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation. Transplantation 2004, 78, 509–515.
- Sibley, R.K.; Sutherland, D.E.; Goetz, F.; Michael, A.F. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest 1985, 53, 132–144.
- Tyden, G.; Reinholt, F.P.; Sundkvist, G.; Bolinder, J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N. Engl. J. Med 1996, 335, 860–863.
- Gysemans, C.A.; Waer, M.; Valckx, D.; Laureys, J.M.; Mihkalsky, D.; Bouillon, R.; Mathieu, C. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes 2000, 49, 1992–1997.
- Sapmaz, E.; Ayar, A.; Celik, H.; Sapmaz, T.; Kilic, N.; Yasar, M.A. Effects of melatonin and oxytetracycline in autologous intraperitoneal ovary transplantation in rats. Neuro Endocrinol. Lett 2003, 24, 350–354.
- Lin, G.J.; Huang, S.H.; Chen, Y.W.; Hueng, D.Y.; Chien, M.W.; Chia, W.T.; Chang, D.M.; Sytwu, H.K. Melatonin prolongs islet graft survival in diabetic NOD mice. J. Pineal Res 2009, 47, 284–292.
- Zhang, Y.C.; Pileggi, A.; Agarwal, A.; Molano, R.D.; Powers, M.; Brusko, T.; Wasserfall, C.; Goudy, K.; Zahr, E.; Poggioli, R.; et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003, 52, 708–716.
- Kim, Y.H.; Lim, D.G.; Wee, Y.M.; Kim, J.H.; Yun, C.O.; Choi, M.Y.; Park, Y.H.; Kim, S.C.; Han, D.J. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant 2008, 17, 609–618.
- Abraham, C.; Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med 2009, 361, 2066–2078.
- Strober, W.; Fuss, I.J.; Blumberg, R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol 2002, 20, 495–549.
- Sartor, R.B. Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol 2006, 3, 390–407.
- Neurath, M.F.; Finotto, S. The many roads to inflammatory bowel diseases. Immunity 2006, 25, 189–191.
- Fuss, I.J.; Neurath, M.; Boirivant, M.; Klein, J.S.; de la Motte, C.; Strong, S.A.; Fiocchi, C.; Strober, W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol 1996, 157, 1261–1270.
- Barrett, J.C.; Hansoul, S.; Nicolae, D.L.; Cho, J.H.; Duerr, R.H.; Rioux, J.D.; Brant, S.R.; Silverberg, M.S.; Taylor, K.D.; Barmada, M.M.; et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet 2008, 40, 955–962.
- Fujino, S.; Andoh, A.; Bamba, S.; Ogawa, A.; Hata, K.; Araki, Y.; Bamba, T.; Fujiyama, Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52, 65–70.
- Elson, C.O.; Cong, Y.; Weaver, C.T.; Schoeb, T.R.; McClanahan, T.K.; Fick, R.B.; Kastelein, R.A. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132, 2359–2370.
- Hue, S.; Ahern, P.; Buonocore, S.; Kullberg, M.C.; Cua, D.J.; McKenzie, B.S.; Powrie, F.; Maloy, K.J. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med 2006, 203, 2473–2483.
- Pentney, P.T.; Bubenik, G.A. Melatonin reduces the severity of dextran-induced colitis in mice. J. Pineal Res 1995, 19, 31–39.
- Nosal’ova, V.; Zeman, M.; Cerna, S.; Navarova, J.; Zakalova, M. Protective effect of melatonin in acetic acid induced colitis in rats. J. Pineal Res 2007, 42, 364–370.
- Dong, W.G.; Mei, Q.; Yu, J.P.; Xu, J.M.; Xiang, L.; Xu, Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol 2003, 9, 1307–1311.
- Cuzzocrea, S.; Mazzon, E.; Serraino, I.; Lepore, V.; Terranova, M.L.; Ciccolo, A.; Caputi, A.P. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J. Pineal Res 2001, 30, 1–12.
- Mazzon, E.; Esposito, E.; Crisafulli, C.; Riccardi, L.; Muia, C.; di Bella, P.; Meli, R.; Cuzzocrea, S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J. Pineal Res. 2006, 41, 363–373.
- Esposito, E.; Mazzon, E.; Riccardi, L.; Caminiti, R.; Meli, R.; Cuzzocrea, S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J. Pineal Res 2008, 45, 166–173.
- Necefli, A.; Tulumoglu, B.; Giris, M.; Barbaros, U.; Gunduz, M.; Olgac, V.; Guloglu, R.; Toker, G. The effect of melatonin on TNBS-induced colitis. Dig. Dis. Sci 2006, 51, 1538–1545.
- Li, J.H.; Yu, J.P.; Yu, H.G.; Xu, X.M.; Yu, L.L.; Liu, J.; Luo, H.S. Melatonin reduces inflammatory injury through inhibiting NF-κB activation in rats with colitis. Mediators Inflamm 2005, 2005, 185–193.
- Mei, Q.; Xu, J.M.; Xiang, L.; Hu, Y.M.; Hu, X.P.; Xu, Z.W. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad. Med. J 2005, 81, 667–672.
- Marquez, E.; Sanchez-Fidalgo, S.; Calvo, J.R.; la de Lastra, C.A.; Motilva, V. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J. Pineal Res 2006, 40, 48–55.
- Chojnacki, C.; Wisniewska-Jarosinska, M.; Walecka-Kapica, E.; Klupinska, G.; Jaworek, J.; Chojnacki, J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J. Physiol. Pharmacol 2011, 62, 327–334.
- Prud'homme, G.J. Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors. J. Gene Med 2000, 2, 222–232.
- Ruiz, P.A.; Shkoda, A.; Kim, S.C.; Sartor, R.B.; Haller, D. IL-10 gene-deficient mice lack TGF-beta/Smad-mediated TLR2 degradation and fail to inhibit proinflammatory gene expression in intestinal epithelial cells under conditions of chronic inflammation. Ann. N. Y. Acad. Sci 2006, 1072, 389–394.
- Balasa, B.; Van Gunst, K.; Jung, N.; Katz, J.D.; Sarvetnick, N. IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. Cell. Immunol 2000, 202, 97–102.
- Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75, 263–274.
- Groux, H.; O’Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E.; Roncarolo, M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389, 737–742.
- Hardeland, R.; Pandi-Perumal, S.R. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab 2005, 2, 22.
- Kucukakin, B.; Lykkesfeldt, J.; Nielsen, H.J.; Reiter, R.J.; Rosenberg, J.; Gogenur, I. Utility of melatonin to treat surgical stress after major vascular surgery—A safety study. J. Pineal Res 2008, 44, 426–431.
- Gitto, E.; Pellegrino, S.; Gitto, P.; Barberi, I.; Reiter, R.J. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J. Pineal Res 2009, 46, 128–139.
- Kennaway, D.J.; Seamark, R.F. Circulating levels of melatonin following its oral administration or subcutaneous injection in sheep and goats. Aust. J. Biol. Sci 1980, 33, 349–353.
- DeMuro, R.L.; Nafziger, A.N.; Blask, D.E.; Menhinick, A.M.; Bertino, J.S., Jr. The absolute bioavailability of oral melatonin. J. Clin. Pharmacol. 2000, 40, 781–784.
- Jacob, S.; Poeggeler, B.; Weishaupt, J.H.; Siren, A.L.; Hardeland, R.; Bahr, M.; Ehrenreich, H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): High tolerability of daily oral melatonin administration in ALS patients. J. Pineal Res 2002, 33, 186–187.
- Weishaupt, J.H.; Bartels, C.; Polking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Huther, G.; et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res 2006, 41, 313–323.
|Table 1. The effects of melatonin in the animal model of autoimmune diseases.|
|Clinical diseases||Animal models||Melatonin treatment||Results||Reference|
|Multiple sclerosis||EAE||Receptor antagonist (luzindole)||Suppresses the onset of EAE|||
|EAE||5 mg/kg, orally||Reduces the incidence and severity of clinical signs|||
|Systemic lupus erythematosus||MRL/MpJ-lprFas mice||30 mg/kg, dw||Ameliorates disease in females, whereas exacerbates disease in males|||
|MRL/MpJ-lprFas mice||30 mg/kg, dw, combined with testosterone in females, with estradiol in males||Decrease in total serum IgG, IgM, anti-ddsDNA, and anti-CII autoantibodies titers|||
|pristane-induced lupus in Balb/c mice||0.01, 0.1, 1.0 mg/kg, intragastric||Display a beneficial effect on disease|||
|Membranous nephritis in Balb/c mice||20 mg/kg, sc.||Suppresses the pathological injury of glomeruli and deposition of immune complexes|||
|Rheumatoid arthritis||CIA in DBA/1 mice||Constant darkness||Exaggerates severity and chronicity of arthritis|||
|CIA in DBA/1 mice||1 mg/kg, sc.||Increase arthritis severity|||
|CIA in DBA/1 and NFR/N mice||Pinealectomy||Ameliorates arthritis in both strain|||
|AA in SD rats||1, 10, 100 μg/kg, intragastric||Ameliorates arthritis and inhibits inflammatory response|||
|CIA in Wistar rats||30 μg/mouse, sc.||No significant effect in hitopathologic features, increases the levels of IL-1β and IL-6 in serum|||
|CIA in DBA/1 mice||10 mg/kg, i.p.||Increases paw thickness and joint destruction|||
|Type 1 diabetes mellitus||NOD mice||pinealectomy||Promotes disease onset|||
|NOD mice||4 mg/kg, sc.||Protects from the development of disease|||
|NOD mice||200 mg/kg, sc.||Prolongs islet grafts survival in NOD recipient|||
|Inflammatory bowel disease||DSS-induced colitis in mice||150 μg/kg, i.p.||Reduces the severity of colitis|||
|DNBS-colitis in SD rats||15 mg/kg, i.p.||Reduces severity of colitis|||
|TNBS and acetic acid-colitis in SD rats||5 and 10 mg/kg||Protects colonic injury in both colitis models|||
|TNBS-colitis in SD rats||2.5, 5, 10 mg/kg||Reduces colonic inflammatory injury|||
|TNBS-colitis in SD rats||2.5, 5, 10 mg/kg, intracolonic||Attenuates colonic injury|||
|TNBS-colitis in Wistar-albino rats||10 mg/kg, i.p.||Decreases colitis scores|||
|DNBS-colitis in SD rats||15 mg/kg, i.p.||Attenuates colonic injury|||
|TNBS-colitis in Wistar rats||acute administration: 0.5, 1, 2 mg/kg, i.p.; chronic administration: 1 and 2 mg/kg, i.p.||Short-term administration protects from colitis while chronic administration aggravates colitis|||
|Acetic acid-colitis in Wistar rats||10 mg/kg, i.p. and intracolonic||Protects from colitis induced colonic damage|||
|DNBS-colitis in SD rats||15 mg/kg, i.p.||Reduces colonic injury|||
© 2013 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).